News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Phosphate Therapeutics Announces Completion Of Subject Recruitment Into The PEACH Pivotal Phase 2 Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 2/26/2015
ISA Pharmaceuticals Announces Start Of First Phase 1/2 Clinical Trial Of Its SLP®-AMPLIVANT® Conjugates 2/26/2015
Dilafor Announces Positive Results From A Multi Dosing Safety And Pharmacokinetic Clinical Study 2/25/2015
Teva Pharmaceutical Industries (TEVA) Announces Positive Results For TEV-48125 In Phase IIb Chronic Migraine Study Meeting Primary And Secondary Endpoints 2/24/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
Emisphere Technologies, Inc. (EMIS) Highlights Positive Phase 2 Og217sc Data From Eligen Licensee Novo Nordisk A/S (NVO) 2/23/2015
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015
Galapagos NV (GLPG.BR) Reports That The Last Patient In Darwin 1 Has Completed 12 Weeks Of Treatment 2/23/2015
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015
Novo Nordisk A/S (NVO) Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabetes 2/20/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase 2 Colorectal Cancer Study 2/18/2015
BioTie Therapies Corp.: BTT1023 Receives Positive Opinion For Orphan Drug Designation From COMP 2/17/2015
VBL Therapeutics (VBLX) Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis 2/17/2015
Protalix Biotherapeutics, Inc. (PLX) Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Amarantus BioSciences, Inc. Announces Publication In BRAIN Of Eltoprazine Phase 2a Clinical Study For Treating Parkinson's Disease Levodopa-Induced Dyskinesia 2/10/2015
Advanced Inhalation Therapies Receives Orphan Drug Designation Of Its Proprietary High Dose Formulation Of Nitric Oxide For Adjunctive Treatment Of Cystic Fibrosis 2/9/2015
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Adocia Reports Positive Results From Phase 2a Clinical Study Of Fast-Acting Insulin, HinsBet 2/5/2015
Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer 2/4/2015
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015
BrainStorm Cell Therapeutics Inc. Announces Positive DSMB Recommendation In Ongoing Phase 2 Trial With NurOwn™ In ALS 2/3/2015
Immuron Release: Patient Recruitment Commenced For Phase 2 NASH Trial 2/3/2015
Genmab A/S (GEN.CO) Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory Multiple Myeloma 2/3/2015
Treatment Of The First HIV Positive Patient In ABIVAX's Phase 2a Clinical Trial With ABX464 2/2/2015
Biomay AG Reports Positive Phase 2b Data With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 1/28/2015
Pivotal Therapeutics Inc. Receives Final Approval For Phase 2a Clinical Trial With PVT-100 1/27/2015
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/26/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/9/2015
Bio Blast Provides Update On Clinical Trial Of Cabaletta™ For Occulopharyngeal Muscular Dystrophy (OPMD) 1/8/2015
GW Pharmaceuticals (GWPH) Provides Update On Epidiolex® Program In Treatment Resistant Childhood Epilepsies 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Galapagos Starts Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 1/8/2015
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 1/8/2015
Herantis Pharma Has Initiated Phase 2 Study With Cis-UCA Eye Drops In Patients With Dry Eye Syndrome, Results Expected In Q3/2015 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Otic Pharma Announces Positive Results From A Phase 2 Trial Of Foamotic Externa, Once-A-Day, Single Antibiotic, Steroid Free Product For Acute Otitis Externa (AOE) 1/7/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit From NurOwn™ 1/5/2015
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 1/2/2015
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
Generon (Shanghai) Corporation Ltd. Presents The Global Phase 2 Study Results For F-627 (Benegrastim) At American Society of Hematology 56th Annual Meeting At San Francisco 12/8/2014
QLT Inc. (QLTI) Announces Results From Proof-of-Concept Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation And/Or Impaired Low Luminance Vision 12/5/2014
Genmab A/S (GEN.CO) Announces Phase 2 Study Of Daratumumab In Non-Hodgkin's Lymphomas 12/4/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014
Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase 2a Trial For The Treatment Of Cholesterol Gallstones 11/13/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy 11/13/2014
Galapagos NV (GLPG.BR) Completes Recruitment For Darwin 1 Study With GLPG0634 (Filgotinib) In RA 11/12/2014
AB Science (AB.PA): The Data And Safety Monitoring Board Recommends The Continuation Of The Phase 2 Study With Masitinib In Advanced Hepatocellular Carcinoma 11/12/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 11/12/2014
Enzymotec Initiates Clinical Study Of Vayarin® In Adult ADHD 11/11/2014
Prima Biomed (PRR.AX) Release: CVac Demonstrates Overall Survival Benefit In Second Remission Ovarian Cancer 11/6/2014
D-Pharm Ltd. Reports First Results From Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 11/4/2014
BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile 11/3/2014
Onxeo: Positive Phase 2 Preliminary Results Of Validive® For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 10/31/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014
Moberg Pharma AB (Formerly known as Moberg Derma): First Patient Included In Phase 2 Study Of BUPI, A Novel Topical Formulation For Treatment Of Oral Pain 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014
Clementia Announces Open-Label Phase 2 Extension Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 10/27/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug 10/15/2014
Tekmira (TKMR)'s Partner Reports Positive Clinical Data For LNP-Enabled Patisiran 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014
Biotron Limited (BIT:AU) Release: BIT225 Trial Results Show Effective Cure Of Hepatitis C 10/10/2014
Galapagos NV (GLPG.BR) Presents Novel Cystic Fibrosis Combination Therapy At NACFC 10/9/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy 10/8/2014
Medgenics, Inc. To Present Initial Clinical Data From MDGN-201 Study At European Society Of Gene And Cell Therapy Congress 10/7/2014
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Initiation Of Phase 2 Trial With FDX104 In Chemotherapy Induced Rash 10/6/2014
Collaboration With Dr. Stephen Waxman Of Yale University To Evaluate Pharmacology Of Nav1.7 Mutations In Chronic Pain Disorders 10/6/2014
Horizon Pharma plc.  (HZNP) Receives Orphan-Drug Designation For ACTIMMUNE(R) (Interferon gamma-1b) In Friedreich's Ataxia 10/6/2014
Galderma Initiates U.S. Study Of Novel Muscle Relaxant For Aesthetic Dermatology And Cosmetic Surgery 10/6/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer 9/30/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN)'s Dupilumab Successful In Phase 2 Study 9/30/2014
Bionomics Limited (BNO.AX) Presents BNC105 Phase 2 Renal Cancer Trial Biomarker Data 9/29/2014
Viralytics Ltd (VLA.AX) Release: Updated Positive Data From Phase 2 Trial Of CAVATAK In Late-Stage Melanoma 9/29/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
BioBlast Pharma (ORPN) Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
Prosonix Confirms The Potential Of Its Multi-Component Particle™ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014
Amarantus BioSciences, Inc. Announces Positive MANF Ocular Toxicology Data 9/9/2014
AstraZeneca PLC (AZN)’s Phase 2 Lung Drug Data Gives Mixed Messages 9/9/2014
ProSensa Holding N.V. (RNA) Announces Lancet Neurology Publication Of An Exploratory Phase 2 Study (DEMAND II) Demonstrating Efficacy And Safety Of Drisapersen In Patients With Duchenne Muscular Dystrophy 9/8/2014
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014
Kamada Ltd. (KMDA) Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency 9/4/2014
Oncolytics Biotech Inc. (ONC.TO) Neuroderm Announces Start Of Phase 2a Study Of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration For Patients With Severe Parkinson's Disease 9/3/2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer (PFE) Bid; Start Of New Cancer Trial 9/2/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25 7/2/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014



//-->